If you liked this article you might like

Biotech Movers: Shire Rises on Encouraging Angioedema Results
Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth
Biotech Buoyed by Deal Talk
5 Toxic Stocks to Avoid